Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Moderate and Severe Plaque Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    275 result(s) found for: Moderate and Severe Plaque Psoriasis. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000164-28 Sponsor Protocol Number: 8400-201 Start Date*: 2013-04-04
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050577 Psoriatic plaque LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003287-37 Sponsor Protocol Number: EMR200588-002 Start Date*: 2016-03-15
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro...
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-002970-22 Sponsor Protocol Number: I1F-MC-RHAZ(c) Start Date*: 2012-05-31
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHAZ A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extensio...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004061-39 Sponsor Protocol Number: CNTO1959PSO4015 Start Date*: 2021-10-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003513-28 Sponsor Protocol Number: PS0005 Start Date*: 2015-03-27
    Sponsor Name:UCB Biopharma, SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-004320-16 Sponsor Protocol Number: 77242113PSO2002 Start Date*: 2022-07-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002887-59 Sponsor Protocol Number: VTX958-201 Start Date*: 2023-03-01
    Sponsor Name:Ventyx Biosciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000121-40 Sponsor Protocol Number: CNTO1275PSO3013 Start Date*: 2016-05-02
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pedia...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) PL (Completed) FR (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023512-13 Sponsor Protocol Number: CAIN457A2302 Start Date*: 2011-05-24
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and lo...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) IS (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002628-14 Sponsor Protocol Number: I1F-MC-RHBQ Start Date*: 2016-06-08
    Sponsor Name: [...]
    1.
    2. Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis
    Medical condition: Moderate-to-severe genital psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10063407 Psoriasis genital LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006057-28 Sponsor Protocol Number: CAIN457A2308 Start Date*: 2012-06-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001066-17 Sponsor Protocol Number: CNTO1959PSO2001 Start Date*: 2012-04-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001630-14 Sponsor Protocol Number: DRN0307 Start Date*: 2007-10-30
    Sponsor Name:University Medical Centre St. Radboud, Department of Dermatology
    Full Title: Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003812-19 Sponsor Protocol Number: ZPL389/102 Start Date*: 2015-12-07
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT ...
    Medical condition: PLAQUE PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-017234-51 Sponsor Protocol Number: CAIN457A2211E1 Start Date*: 2010-04-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter extension trial of subcutaneously administered AIN457 in patients with moderate to severe chronic plaque-type psoriasis
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IS (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-001531-12 Sponsor Protocol Number: LRP/LNP1955/2016/003 Start Date*: 2016-08-16
    Sponsor Name:Lupin Limited
    Full Title: A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, and Safety of LNP1955 in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018190 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-004620-60 Sponsor Protocol Number: CAIN457A2324 Start Date*: 2018-06-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 ...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022228-66 Sponsor Protocol Number: CAIN457A2303 Start Date*: 2011-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) IS (Completed) HU (Completed) SE (Completed) BE (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002532-24 Sponsor Protocol Number: 0155/2018 Start Date*: 2018-12-27
    Sponsor Name:HELM AG
    Full Title: A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to origi...
    Medical condition: mild to moderate plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002022-37 Sponsor Protocol Number: CNTO1959PSO3006 Start Date*: 2016-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects ...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:33:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA